BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18600532)

  • 1. Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy.
    van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Bakker PJ; Guchelaar HJ; Richel DJ
    Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):726-32. PubMed ID: 18600532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.
    van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Van Lenthe H; Bakker PJ; Richel DJ; Guchelaar HJ
    Eur J Cancer; 2007 Jan; 43(2):459-65. PubMed ID: 17097873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients.
    Reerink O; Mulder NH; Szabo BG; Hospers GA
    Anticancer Res; 2004; 24(3b):1969-71. PubMed ID: 15274386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.
    van Kuilenburg AB
    Cancer Invest; 2006 Mar; 24(2):215-7. PubMed ID: 16537192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
    Saeki H; Ito S; Futatsugi M; Kimura Y; Ohga T; Sugimachi K
    Anticancer Res; 2002; 22(6B):3789-92. PubMed ID: 12552994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
    Magné N; Etienne-Grimaldi MC; Cals L; Renée N; Formento JL; Francoual M; Milano G
    Br J Clin Pharmacol; 2007 Aug; 64(2):237-40. PubMed ID: 17335544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
    Dong QM; He YJ; Li S; Zhou ZM; Zhang L; Zhou ZW; Xia ZJ; Li YY
    Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
    van Kuilenburg AB; De Abreu RA; van Gennip AH
    Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
    Van Kuilenburg AB; van Lenthe H; Blom MJ; Mul EP; Van Gennip AH
    Br J Cancer; 1999 Feb; 79(3-4):620-6. PubMed ID: 10027339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
    Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
    Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
    Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
    van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
    Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
    Lu Z; Zhang R; Diasio RB
    Cancer Res; 1993 Nov; 53(22):5433-8. PubMed ID: 8221682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.